Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc.

    NEXT STORY
    Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
    PREV STORY
    EnvoyAI Made Available to Over 200 UK Healthcare Locations
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Teleflex to Present at the 40th Annual Goldman Sachs Global Healthcare Conference

    author_avatar
    NASDAQ Market News

    CB2 Insights to Host Q12019 Earnings Call on May 31, 2019

    author_avatar
    NASDAQ Market News

    Zafgen’s Phase 2b Trial of Beloranib in Severe Obesity Complicated by Type 2 Diabetes Achieves Primary Efficacy Endpoint

    - Beloranib demonstrates statistically and clinically significant improvements in body weight and glycemic control ...

    author_avatar
    NASDAQ Market News